Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Data from phase III trials support safety and efficacy of tenofovir DF in CHB patients

Nov. 18, 2009

SB-939 shows favorable PK, PD and safety in phase I trial in advanced solid tumors

Nov. 17, 2009

IMO-2125 shows promising anti-HCV activity in preclinical evaluation

Nov. 17, 2009

Taribavirin has anemia benefits versus ribavirin in HCV patients

Nov. 17, 2009

Vicriviroc exhibits long-term safety in phase II HIV trials, phase III trials under way

Nov. 17, 2009

PEG-Interferon lambda effective in HCV genotype 1 relapsed patients

Nov. 17, 2009

Entecavir exhibits superior antiviral activity to adefovir in CHB patients

Nov. 17, 2009

Promising preclinical and phase IIa data on S/GSK-1349572 disclosed

Nov. 16, 2009

Phase I/II data show VIR-576 to be safe and effective in HIV

Nov. 16, 2009

BMS-650032 shows potent anti-HCV activity in two phase II trials

Nov. 16, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...